Repligen (RGEN) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Repligen Reports Second Quarter 2017 Financial Results
August 3, 2017 7:31 AM EDTRecord quarterly revenue of $32.5 millionFirst half 2017 revenue growth of 16% or 18% at constant currencyEnters agreement to acquire Spectrum, Inc., which closed August 1Prices follow-on offering which netted proceeds of $129 million Raises EPS guidance for 2017
WALTHAM, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter ended June 30, 2017. Detailed in this press release are the Company's performance highlights for the quarter,... More
